A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol(TM) Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator

Trial Profile

A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol(TM) Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs PXVX 0200 (Primary) ; Cholera vaccine inactivated
  • Indications Cholera
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 16 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 28 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top